Collegium Pharmaceutical Inc (NASDAQ: COLL) has a higher price-to-earnings ratio of 14.38x compared to its average ratio. COLL has 36-month beta value of 0.81. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for COLL is 31.12M, and currently, short sellers hold a 19.25% ratio of that float. The average trading volume of COLL on January 10, 2025 was 431.58K shares.
COLL) stock’s latest price update
Collegium Pharmaceutical Inc (NASDAQ: COLL) has seen a rise in its stock price by 14.41 in relation to its previous close of 29.14. However, the company has experienced a 16.37% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-08 that – Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.
COLL’s Market Performance
Collegium Pharmaceutical Inc (COLL) has seen a 16.37% rise in stock performance for the week, with a 11.24% gain in the past month and a -12.31% plunge in the past quarter. The volatility ratio for the week is 6.31%, and the volatility levels for the past 30 days are at 4.06% for COLL. The simple moving average for the last 20 days is 11.91% for COLL stock, with a simple moving average of -3.27% for the last 200 days.
Analysts’ Opinion of COLL
Many brokerage firms have already submitted their reports for COLL stocks, with H.C. Wainwright repeating the rating for COLL by listing it as a “Buy.” The predicted price for COLL in the upcoming period, according to H.C. Wainwright is $47 based on the research report published on July 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see COLL reach a price target of $44, previously predicting the price at $41. The rating they have provided for COLL stocks is “Buy” according to the report published on June 07th, 2024.
Piper Sandler gave a rating of “Neutral” to COLL, setting the target price at $39 in the report published on May 10th of the previous year.
COLL Trading at 7.85% from the 50-Day Moving Average
After a stumble in the market that brought COLL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.16% of loss for the given period.
Volatility was left at 4.06%, however, over the last 30 days, the volatility rate increased by 6.31%, as shares surge +8.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.92% lower at present.
During the last 5 trading sessions, COLL rose by +16.37%, which changed the moving average for the period of 200-days by -16.06% in comparison to the 20-day moving average, which settled at $29.79. In addition, Collegium Pharmaceutical Inc saw 16.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COLL starting from Smith Thomas B, who sale 9,593 shares at the price of $36.62 back on Sep 13 ’24. After this action, Smith Thomas B now owns 53,816 shares of Collegium Pharmaceutical Inc, valued at $351,320 using the latest closing price.
Smith Thomas B, the Officer of Collegium Pharmaceutical Inc, proposed sale 373 shares at $36.98 during a trade that took place back on Sep 13 ’24, which means that Smith Thomas B is holding shares at $13,794 based on the most recent closing price.
Stock Fundamentals for COLL
Current profitability levels for the company are sitting at:
- 0.32 for the present operating margin
- 0.62 for the gross margin
The net margin for Collegium Pharmaceutical Inc stands at 0.15. The total capital return value is set at 0.16. Equity return is now at value 42.89, with 6.30 for asset returns.
Based on Collegium Pharmaceutical Inc (COLL), the company’s capital structure generated 0.79 points at debt to capital in total, while cash flow to debt ratio is standing at 0.22. The debt to equity ratio resting at 3.7. The interest coverage ratio of the stock is 2.74.
Currently, EBITDA for the company is 308.33 million with net debt to EBITDA at 2.41. When we switch over and look at the enterprise to sales, we see a ratio of 3.19. The receivables turnover for the company is 2.62for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.
Conclusion
To put it simply, Collegium Pharmaceutical Inc (COLL) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
